Insider transactions

Clay B Siegall

CIK 1167496 · President and CEO · last filed 2026-07-27

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$17.80M
Companies
8
Total Filings
211
Lifetime Open-Market Net
-$226.50M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

SGEN price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
21823 30TH DR SE
BOTHELL, WA 98021
Related Filers
Ultragenyx Pharmaceutical Inc. — 10 joint filings, latest 2020-08-11
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
IMNM President and CEO 870,704 $18.71 $16.29M $6.76M 11 2026-07-27
STTK Director 318,608 $4.62 $1.47M $250.0K 7 2026-06-11
Tourmaline Bio, Inc. (TRML) Delisted Director — $47.98 — $0 4 2025-10-28
Seagen Inc. (SGEN) Delisted President & CEO 676,653 $228.74 $154.78M -$229.11M 168 2022-05-13
NRIX Director — $15.30 — $0 2 2022-05-06
RARE Director 2,550 $15.43 $39.3K -$2.97M 9 2020-08-11
ALDER BIOPHARMACEUTICALS INC (ALDR) Delisted Director 31,714 — — -$1.44M 7 2019-05-28
SYNLOGIC, INC. (MIRN) Delisted Director — — — $0 1 2016-09-06

Recent Filings · Page 7 of 22

211 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2020-02-12 Seagen Inc. (SGEN) Delisted Mixed — -$2.92M EDGAR
2020-01-10 Seagen Inc. (SGEN) Delisted Mixed — -$2.83M EDGAR
2019-12-23 Seagen Inc. (SGEN) Delisted Grant (A) +3,100 $0 EDGAR
2019-12-10 Seagen Inc. (SGEN) Delisted Mixed — -$2.92M EDGAR
2019-11-12 Seagen Inc. (SGEN) Delisted Mixed — -$2.72M EDGAR
2019-10-24 — Mixed −31,714 -$570.9K
2019-10-10 Seagen Inc. (SGEN) Delisted Mixed — -$2.01M EDGAR
2019-09-10 Seagen Inc. (SGEN) Delisted Mixed — -$1.60M EDGAR
2019-09-04 Seagen Inc. (SGEN) Delisted Mixed +38,341 -$686.3K EDGAR
2019-08-30 Seagen Inc. (SGEN) Delisted Sell (S) −28,951 -$2.12M EDGAR
Showing 61–70 of 211
Page 7 of 22
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.